Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19
Condition: SARS-CoV-2 Intervention: Sponsor: ModernaTX, Inc. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine
Condition: SARS-CoV-2 Intervention: Sponsor: ModernaTX, Inc. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19
Condition: SARS-CoV-2 Intervention: Sponsor: ModernaTX, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19
Condition: SARS-CoV-2 Intervention: Sponsor: ModernaTX, Inc. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine
Condition: SARS-CoV-2 Intervention: Sponsor: ModernaTX, Inc. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19
Condition: SARS-CoV-2 Intervention: Sponsor: ModernaTX, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19
Condition: SARS-CoV-2 Intervention: Sponsor: ModernaTX, Inc. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine
Condition: SARS-CoV-2 Intervention: Sponsor: ModernaTX, Inc. Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19
Condition: SARS-CoV-2 Intervention: Sponsor: ModernaTX, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 8, 2023 Category: Research Source Type: clinical trials
A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy Participants
Condition: Healthy Volunteers Interventions: Drug: GSBR-1290; Other: Placebo Sponsor: Gasherbrum Bio, Inc Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 7, 2023 Category: Research Source Type: clinical trials
